FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330307525> ?p ?o ?g. }

• W2330307525 abstract "Reactivation of Toxoplasma gondii infections and serious clinical manifestations such as encephalitis may develop in immunocompromised subjects and AIDS patients. Different protocols are used for the treatment of toxoplasmosis in high-risk patient groups, however life-long prophylactic therapy against reactivation risk in AIDS patients may lead to several undesired results. Atovaquone is an effective antiprotozoal agent against toxoplasmosis with minor side effects. On the other hand, Astragalus membranaceus root extract (AmE) has been shown to have immunomodulatory and antimicrobial activities, empowering immunity by enhancing proliferation and activation of phagocytic cells mainly macrophages, and inducing Th1 type immune response. The aim of this study was to investigate the effectiveness of atovaquone alone and in combination with AmE, in the treatment of toxoplasmosis, and on the levels of IL-2, IL-12 and IFN-γ in experimentally infected mice with T.gondii. For this purpose, four experimental groups, each consisting of eight BALB/c mice, were set with the approval of Ethics Committee for the Animal Experiments. All the mice were infected with 0.5 ml of a suspension containing 2 x 104/ml trophozoites prepared from T.gondii RH strain by intraperitoneal injection. Twenty-four hours after the infection, atovaquone (100 mg/kg/day) was given to atovaquone group, AmE (0.075 mg/g) to astragalus group and atovaquone (100 mg/kg/day) plus AmE (0.075 mg/g) to Atovaquone + Astragalus (Ato + Astra) group by oral gavage. The mice in the fourth group, which was the control group, were all infected but untreated. The above administrations were carried out for seven days. On the 8th day peritoneal fluids of mice were collected under anaesthesia and trophozoite numbers per 1 ml were detected by counting on the Thoma slide. In addition, the heart bloods of mice were drawn and IL-2, IL-12, IFN-γ levels were determined in serum samples by using commercial ELISA kits (eBioscience, Austria). The mean number of trophozoites in Ato + Astra group was found significantly lower than the number of trophozoites in the other three groups (p< 0.05). The number of trophozoites in the atovaquone and astragalus groups were found significantly lower than the number of trophozoites in the control group (p< 0.05). There was a significant increase in IL-2 levels of astragalus group compared with the other three groups, in addition when IL-2 levels of Ato + Astra group were compared with ones in other three groups, a significant decrease was noticed (p< 0.05). There was a definite increase in IL-12 levels of atovaquone, astragalus and the control groups compared to those in Ato + Astra group (p< 0.05). A significant increase was found in IFN-γ levels in atovaquone and Ato + Astra groups compared with those in the control group (p< 0.05). Within the reach of our literature survey, this study was the first research in which the effectiveness of the combination of atovaquone and AmE was investigated in the treatment of acute toxoplasmosis. The results of our study suggested that there might be a synergy between atovaquone and AmE in the treatment of acute toxoplasmosis. In case these results are supported by further studies, atovaquone and AmE combination may have a potential to be used for therapy in immunocompromized patients such as AIDS patients who have a risk for toxoplasmosis." @default.
• W2330307525 created "2016-06-24" @default.
• W2330307525 creator A5013678069 @default.
• W2330307525 creator A5019246065 @default.
• W2330307525 creator A5048619929 @default.
• W2330307525 creator A5085563978 @default.
• W2330307525 date "2014-10-28" @default.
• W2330307525 modified "2023-09-23" @default.
• W2330307525 title "Effects of Atovaquone and Astragalus Combination on the Treatment and IL-2, IL-12, IFN-g Levels on Mouse Models of Acute Toxoplasmosis" @default.
• W2330307525 doi "https://doi.org/10.5578/mb.8025" @default.
• W2330307525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25492659" @default.
• W2330307525 hasPublicationYear "2014" @default.
• W2330307525 type Work @default.
• W2330307525 sameAs 2330307525 @default.
• W2330307525 citedByCount "3" @default.
• W2330307525 countsByYear W23303075252016 @default.
• W2330307525 countsByYear W23303075252017 @default.
• W2330307525 countsByYear W23303075252020 @default.
• W2330307525 crossrefType "journal-article" @default.
• W2330307525 hasAuthorship W2330307525A5013678069 @default.
• W2330307525 hasAuthorship W2330307525A5019246065 @default.
• W2330307525 hasAuthorship W2330307525A5048619929 @default.
• W2330307525 hasAuthorship W2330307525A5085563978 @default.
• W2330307525 hasConcept C142724271 @default.
• W2330307525 hasConcept C159654299 @default.
• W2330307525 hasConcept C188947578 @default.
• W2330307525 hasConcept C203014093 @default.
• W2330307525 hasConcept C204787440 @default.
• W2330307525 hasConcept C2778048844 @default.
• W2330307525 hasConcept C2778062946 @default.
• W2330307525 hasConcept C2778128430 @default.
• W2330307525 hasConcept C2778371730 @default.
• W2330307525 hasConcept C2779124865 @default.
• W2330307525 hasConcept C2779341262 @default.
• W2330307525 hasConcept C2780798337 @default.
• W2330307525 hasConcept C71924100 @default.
• W2330307525 hasConcept C8891405 @default.
• W2330307525 hasConcept C98274493 @default.
• W2330307525 hasConceptScore W2330307525C142724271 @default.
• W2330307525 hasConceptScore W2330307525C159654299 @default.
• W2330307525 hasConceptScore W2330307525C188947578 @default.
• W2330307525 hasConceptScore W2330307525C203014093 @default.
• W2330307525 hasConceptScore W2330307525C204787440 @default.
• W2330307525 hasConceptScore W2330307525C2778048844 @default.
• W2330307525 hasConceptScore W2330307525C2778062946 @default.
• W2330307525 hasConceptScore W2330307525C2778128430 @default.
• W2330307525 hasConceptScore W2330307525C2778371730 @default.
• W2330307525 hasConceptScore W2330307525C2779124865 @default.
• W2330307525 hasConceptScore W2330307525C2779341262 @default.
• W2330307525 hasConceptScore W2330307525C2780798337 @default.
• W2330307525 hasConceptScore W2330307525C71924100 @default.
• W2330307525 hasConceptScore W2330307525C8891405 @default.
• W2330307525 hasConceptScore W2330307525C98274493 @default.
• W2330307525 hasLocation W23303075251 @default.
• W2330307525 hasLocation W23303075252 @default.
• W2330307525 hasOpenAccess W2330307525 @default.
• W2330307525 hasPrimaryLocation W23303075251 @default.
• W2330307525 hasRelatedWork W14993635 @default.
• W2330307525 hasRelatedWork W2125722420 @default.
• W2330307525 hasRelatedWork W2214102134 @default.
• W2330307525 hasRelatedWork W2325474553 @default.
• W2330307525 hasRelatedWork W2330307525 @default.
• W2330307525 hasRelatedWork W241118077 @default.
• W2330307525 hasRelatedWork W3043615614 @default.
• W2330307525 hasRelatedWork W3107332527 @default.
• W2330307525 hasRelatedWork W3202693663 @default.
• W2330307525 hasRelatedWork W866715081 @default.
• W2330307525 isParatext "false" @default.
• W2330307525 isRetracted "false" @default.
• W2330307525 magId "2330307525" @default.
• W2330307525 workType "article" @default.